Miquel Aranda

727 total citations
4 papers, 284 citations indexed

About

Miquel Aranda is a scholar working on Infectious Diseases, Virology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Miquel Aranda has authored 4 papers receiving a total of 284 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Infectious Diseases, 3 papers in Virology and 1 paper in Pulmonary and Respiratory Medicine. Recurrent topics in Miquel Aranda's work include HIV Research and Treatment (3 papers), HIV/AIDS Research and Interventions (2 papers) and HIV/AIDS drug development and treatment (2 papers). Miquel Aranda is often cited by papers focused on HIV Research and Treatment (3 papers), HIV/AIDS Research and Interventions (2 papers) and HIV/AIDS drug development and treatment (2 papers). Miquel Aranda collaborates with scholars based in Spain. Miquel Aranda's co-authors include Esteban Ribera, Estebán Martínez, Josep M. Llibre, David Dalmau, Ferrán Segura, Hernando Knobel, Daniel Podzamczer, Peré Domingo, Ana Cruceta and Lluís Force and has published in prestigious journals such as New England Journal of Medicine, AIDS and AIDS Research and Human Retroviruses.

In The Last Decade

Miquel Aranda

4 papers receiving 273 citations

Peers

Miquel Aranda
Concepción Cepeda Spain
Ana Cruceta Spain
Philip Lackey United States
David Shamblaw United States
Sílvia Gel Spain
Sushma Kumar United States
Cal Cohen United States
Jesús Santos Spain
Anne Maagaard Norway
Ya-Pei Liu United States
Concepción Cepeda Spain
Miquel Aranda
Citations per year, relative to Miquel Aranda Miquel Aranda (= 1×) peers Concepción Cepeda

Countries citing papers authored by Miquel Aranda

Since Specialization
Citations

This map shows the geographic impact of Miquel Aranda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miquel Aranda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miquel Aranda more than expected).

Fields of papers citing papers by Miquel Aranda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miquel Aranda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miquel Aranda. The network helps show where Miquel Aranda may publish in the future.

Co-authorship network of co-authors of Miquel Aranda

This figure shows the co-authorship network connecting the top 25 collaborators of Miquel Aranda. A scholar is included among the top collaborators of Miquel Aranda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miquel Aranda. Miquel Aranda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

4 of 4 papers shown
1.
Aranda, Miquel, et al.. (2013). DGI-066 Survival Study of Patients with Non-Small Cell Lung Cancer Treated with Erlotinib. European Journal of Hospital Pharmacy. 20(Suppl 1). A120.1–A120. 1 indexed citations
2.
Podzamczer, Daniel, Elena Ferrer, Estebán Martínez, et al.. (2009). How Much Fat Loss Is Needed for Lipoatrophy to Become Clinically Evident?. AIDS Research and Human Retroviruses. 25(6). 563–567. 17 indexed citations
3.
Martínez, Estebán, Juan A. Arnaiz, Daniel Podzamczer, et al.. (2003). Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection. New England Journal of Medicine. 349(11). 1036–1046. 233 indexed citations
4.
García, Felipe, Hernando Knobel, M. A. Sambeat, et al.. (2000). Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the Scan Study. AIDS. 14(16). 2485–2494. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Concepción Cepeda Breakdown of academic impact, for papers by Ana Cruceta Breakdown of academic impact, for papers by Philip Lackey Breakdown of academic impact, for papers by David Shamblaw Breakdown of academic impact, for papers by Sílvia Gel Breakdown of academic impact, for papers by Sushma Kumar Breakdown of academic impact, for papers by Cal Cohen Breakdown of academic impact, for papers by Jesús Santos Breakdown of academic impact, for papers by Anne Maagaard Breakdown of academic impact, for papers by Ya-Pei Liu
Rankless by CCL
2026